Prof Tomas Kalincik
Professorial Fellow, Neurological Outcomes
Department of Medicine
653 Scholarly works
30 Projects
HIGHLIGHTS
2024
Research grants (ARC, NHMRC, MRFF)
New Paradigms in Prevention of Disability in Multiple Sclerosis
2021
Journal article
Associations of Disease-Modifying Therapies with COVID-19 Severity in Multiple Sclerosis
DOI: 10.1212/WNL.00000000000127532018
Research grants (ARC, NHMRC, MRFF)
Arc Training Centre in Cognitive Computing for Medical Technologies (Arc - Central Operating)
2018
Research Grant
Arc Training Centre in Cognitive Computing for Medical Technologies (Arc - Stream 1 & 2)
2015
Journal article
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
DOI: 10.1002/ana.243392014
Journal article
Fingolimod after natalizumab and the risk of short-term relapse
DOI: 10.1212/WNL.00000000000002832013
Journal article
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
DOI: 10.1093/brain/awt281
RECENT SCHOLARLY WORKS
2026
Journal article
A tailored cognitive behavioural therapy intervention for depression in those newly diagnosed with multiple sclerosis (ACTION-MS): A randomised, assessor-blinded, active comparator trial
DOI: 10.1016/j.jad.2026.1219172026
Journal article
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.
DOI: 10.1212/WNL.00000000002180562026
Journal article
Assessing Unmet Social Needs in Multiple Sclerosis Care in Australia: A Qualitative Assessment of Feasibility, Barriers and Enablers
DOI: 10.1111/hex.706912026
Journal article
The relationship between cognitive complaints and burden of non-cognitive symptoms in multiple sclerosis
DOI: 10.1192/bjo.2026.110412026
Journal article
Target trial emulation for causal inference using observational data in neurology
DOI: 10.1016/j.neurol.2026.03.0012026
Journal article
Predicting disease progression in multiple sclerosis with clinically accessible information and technology
DOI: 10.1007/s00415-026-13802-42026
Journal article
Corrigendum to “Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study” [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885] (Multiple Sclerosis and Related Disorders (2026) 106, (S2211034825006236), (10.1016/j.msard.2025.106885))
DOI: 10.1016/j.msard.2026.1071312026
Journal article
Cross-sectional brain volumetric measures and disability outcomes in relapsing–remitting multiple sclerosis
DOI: 10.1007/s00415-026-13788-z